Pluri Inc

PLUR

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Undervalued ASX share searches for cost savings

Cost savings from recent acquisition underpin our earnings growth forecasts.
stocks

Chart of the Week: Where we see opportunities after year end market sell-off

The latest insights from our equity research team.
stocks

Solving the Australian equities conundrum

Where to look in a heavily concentrated index.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,868.2033.10-0.37%
CAC 408,022.6929.82-0.37%
DAX 4024,130.1432.51-0.13%
Dow JONES (US)48,057.75497.461.05%
FTSE 1009,655.5313.520.14%
HKSE25,540.78106.550.42%
NASDAQ23,654.1577.670.33%
Nikkei 22550,602.8052.30-0.10%
NZX 50 Index13,403.6832.620.24%
S&P 5006,886.6846.170.67%
S&P/ASX 2008,579.4031.70-0.37%
SSE Composite Index3,900.509.03-0.23%

Market Movers